Fennec Pharmaceuticals (FENC) EBIAT (2016 - 2025)
Fennec Pharmaceuticals' EBIAT history spans 15 years, with the latest figure at -$4.8 million for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 141.16% year-over-year to -$4.8 million, compared with a TTM value of -$9.7 million through Dec 2025, down 2134.4%, and an annual FY2025 reading of -$9.7 million, down 2134.17% over the prior year.
- EBIAT for Q4 2025 was -$4.8 million at Fennec Pharmaceuticals, down from -$638000.0 in the prior quarter.
- The five-year high for EBIAT was $12.8 million in Q1 2024, with the low at -$8.0 million in Q3 2022.
- Average EBIAT over 5 years is -$3.3 million, with a median of -$4.2 million recorded in 2021.
- Biggest YoY gain for EBIAT was 312.11% in 2024; the steepest drop was 207.18% in 2024.
- Tracing FENC's EBIAT over 5 years: stood at -$4.2 million in 2021, then crashed by 63.58% to -$6.9 million in 2022, then surged by 61.1% to -$2.7 million in 2023, then grew by 25.99% to -$2.0 million in 2024, then plummeted by 141.16% to -$4.8 million in 2025.
- Per Business Quant, the three most recent readings for FENC's EBIAT are -$4.8 million (Q4 2025), -$638000.0 (Q3 2025), and -$3.2 million (Q2 2025).